Skip to Content

Geovax Labs Inc GOVX

Morningstar Rating
$2.71 +0.35 (14.83%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GOVX is trading at a 71% discount.
Price
$2.67
Fair Value
$3.58
Uncertainty
Extreme
1-Star Price
$884.33
5-Star Price
$2.36
Economic Moat
Wgqft
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GOVX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.36
Day Range
$2.382.75
52-Week Range
$2.0411.85
Bid/Ask
$2.56 / $2.74
Market Cap
$5.36 Mil
Volume/Avg
147,895 / 36,876

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
14

Valuation

Metric
GOVX
Price/Earnings (Normalized)
Price/Book Value
0.53
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
GOVX
Quick Ratio
1.79
Current Ratio
2.09
Interest Coverage
Quick Ratio
GOVX

Profitability

Metric
GOVX
Return on Assets (Normalized)
−84.19%
Return on Equity (Normalized)
−105.52%
Return on Invested Capital (Normalized)
−108.68%
Return on Assets
GOVX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRPzksb$541.7 Bil
VRTX
Vertex Pharmaceuticals IncDwhdjt$111.3 Bil
REGN
Regeneron Pharmaceuticals IncJmlswc$109.0 Bil
MRNA
Moderna IncRyc$36.8 Bil
ARGX
argenx SE ADRCtx$24.3 Bil
BNTX
BioNTech SE ADRBtzhv$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncXbhjqw$20.0 Bil
BMRN
Biomarin Pharmaceutical IncSgjnfnp$17.1 Bil
RPRX
Royalty Pharma PLC Class ABxyxk$14.0 Bil
INCY
Incyte CorpGghcsj$13.7 Bil

Sponsor Center